DE60008753D1 - Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen - Google Patents

Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen

Info

Publication number
DE60008753D1
DE60008753D1 DE60008753T DE60008753T DE60008753D1 DE 60008753 D1 DE60008753 D1 DE 60008753D1 DE 60008753 T DE60008753 T DE 60008753T DE 60008753 T DE60008753 T DE 60008753T DE 60008753 D1 DE60008753 D1 DE 60008753D1
Authority
DE
Germany
Prior art keywords
anxieties
treatment
naaladase inhibitors
memory disorder
anxiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60008753T
Other languages
English (en)
Inventor
S Slusher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Corp of North America
Original Assignee
Guilford Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals Inc filed Critical Guilford Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60008753D1 publication Critical patent/DE60008753D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60008753T 1999-07-01 2000-06-30 Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen Expired - Lifetime DE60008753D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/345,782 US6228888B1 (en) 1999-07-01 1999-07-01 Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
PCT/US2000/018260 WO2001001974A2 (en) 1999-07-01 2000-06-30 Naaladase inhibitors in anxiety and memory disorders

Publications (1)

Publication Number Publication Date
DE60008753D1 true DE60008753D1 (de) 2004-04-08

Family

ID=23356457

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60008753T Expired - Lifetime DE60008753D1 (de) 1999-07-01 2000-06-30 Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen

Country Status (9)

Country Link
US (3) US6228888B1 (de)
EP (1) EP1202717B1 (de)
JP (1) JP2003503451A (de)
AT (1) ATE260653T1 (de)
AU (2) AU5785100A (de)
CA (1) CA2378467A1 (de)
DE (1) DE60008753D1 (de)
MX (1) MXPA02000255A (de)
WO (1) WO2001001974A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
CN1314882A (zh) * 1998-07-06 2001-09-26 吉尔福德药物有限公司 用作药物化合物的naalad酶抑制剂和组合物
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
EP1177200B1 (de) 1999-04-28 2005-06-22 Georgetown University Ligande für metabotropische glutamat-rezeptoren
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
MXPA02011921A (es) 2000-05-30 2003-04-22 Guilford Pharm Inc Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
WO2001092273A2 (en) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
WO2003057670A2 (en) * 2001-12-28 2003-07-17 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
US20030162694A1 (en) * 2002-02-04 2003-08-28 James Meyerhoff Novel treatment for pathological aggression
ES2326083T3 (es) * 2003-03-03 2009-09-30 Eisai Corporation Of North America Tiolactonas como inhibidores de naaladasa.
US20090082305A1 (en) * 2005-03-30 2009-03-26 Kyowa Hakko Kogyo Co., Ltd. Method of improving storage stability of substance
ES2819303T3 (es) 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
PT2097111E (pt) 2006-11-08 2015-11-03 Molecular Insight Pharm Inc Heterodímeros de ácido glutámico
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
BR112012000210A2 (pt) 2009-06-15 2019-09-24 Molecular Insight Pharm Inc processo para a produção de heterodímeoros de ácido glutâmico.
EP2338892A1 (de) 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostataspezifische Membranantigen-Inhibitoren
WO2012082903A2 (en) * 2010-12-14 2012-06-21 The Johns Hopkins University Treatment of cognitive impairment in a subject with a neurological autoimmune disease
WO2013103813A1 (en) 2012-01-06 2013-07-11 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix
KR102187940B1 (ko) 2013-01-14 2020-12-07 몰레큘러 인사이트 파마슈티칼스, 인크. 트리아진계 방사성 의약품 및 방사성 이미지화제

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143908A (en) 1986-11-05 1992-09-01 Merck & Co., Inc. Antibacterial agents and potentiators of carbapenem antibiotics
US4927966A (en) * 1987-06-04 1990-05-22 The Research Foundation Of State University Of New York 2-mercaptomethylglutaric acid derivatives
JPH0474197A (ja) 1990-07-12 1992-03-09 Naoyoshi Suzuki 新規な免疫調整生理活性ペプチド
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6384022B1 (en) * 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US6025345A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
EP1005348A1 (de) * 1996-09-27 2000-06-07 Guilford Pharmaceuticals Inc. Naaladase zusammensetzungen und verfahren zur behandlung von glutamatabnormalien und der neuronalen aktivität in tieren
ID18382A (id) * 1996-09-27 1998-04-02 Guilford Pharm Inc Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase
US5981209A (en) 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6121252A (en) 1998-03-30 2000-09-19 Guilford Pharmaceuticals Inc. Phosphinic acid derivatives
CN1314882A (zh) * 1998-07-06 2001-09-26 吉尔福德药物有限公司 用作药物化合物的naalad酶抑制剂和组合物

Also Published As

Publication number Publication date
AU2005237108A1 (en) 2005-12-15
JP2003503451A (ja) 2003-01-28
MXPA02000255A (es) 2002-06-21
AU5785100A (en) 2001-01-22
WO2001001974A2 (en) 2001-01-11
ATE260653T1 (de) 2004-03-15
EP1202717A2 (de) 2002-05-08
CA2378467A1 (en) 2001-01-11
WO2001001974A3 (en) 2002-03-07
US6228888B1 (en) 2001-05-08
US6376478B1 (en) 2002-04-23
EP1202717B1 (de) 2004-03-03
US20030013687A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE554169T1 (de) Smad7-inhibitoren zur behandlung von krankheiten des zns
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE60005952T8 (de) Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten
JO2724B1 (en) 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60130691D1 (de) Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60026581D1 (de) Indolderivate zur behandlung von depression und angstzuständen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8332 No legal effect for de